Search

Your search keyword '"Sprangers, M A G"' showing total 295 results
Start Over Author "Sprangers, M A G"
295 results on '"Sprangers, M A G"'

7. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial

Author

Noordman, B J, Verdam, M G E, Lagarde, S M, Shapiro, J, Hulshof, M C C M, van Berge Henegouwen, M I, Wijnhoven, B P L, Nieuwenhuijzen, G A P, Bonenkamp, J J, Cuesta, M A, Plukker, J Th M, Spillenaar Bilgen, E J, Steyerberg, E W, van der Gaast, A, Sprangers, M A G, and van Lanschot, J J B

Published
2018
Full Text
View/download PDF

12. Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study.

Author

Schuring, N, Markar, S R, Hagens, E R C, Jezerskyte, E, Sprangers, M A G, Lagergren, P, Johar, A, Gisbertz, S S, Henegouwen, M I van Berge, and group, the LASER study

Subjects
ESOPHAGEAL cancer, CHEMORADIOTHERAPY, QUALITY of life, ESOPHAGECTOMY, CANCER chemotherapy, CANCER treatment
Abstract

Curative treatment for locally advanced esophageal cancer consists of (neo)adjuvant treatment followed by esophagectomy. Both neoadjuvant chemoradiotherapy and perioperative chemotherapy improve the 5-year overall survival rate compared with surgery alone. However, it is unknown whether these treatment strategies are associated with differences in long-term health-related quality of life (HRQL). The aim of this study is to compare long-term HRQL in patients after esophagectomy treated with neoadjuvant chemoradiotherapy or perioperative chemotherapy. Disease-free cancer patients having undergone esophagectomy and (neo)adjuvant treatment in one of the participating lasting symptoms after esophageal resection (LASER) study centers between 2010 and 2016, were identified from the LASER study dataset. Included patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), EORTC QLQ-OG25, and LASER questionnaires at least 1 year after the completion of treatment. Long-term HRQL was compared between patients treated with neoadjuvant chemoradiotherapy or perioperative chemotherapy, using univariable and multivariable regression and presented as differences in mean score. Among the 565 included patients, 349 (61.8%) received neoadjuvant chemoradiotherapy, and 216 (38.2%) perioperative chemotherapy. Patients treated with perioperative chemotherapy reported more symptomatology for diarrhea (difference in means 5.93), reflux (difference in means 7.40), and odynophagia (difference in means 4.66). The differences did not exceed the 10 points to be of clinical relevance. No significant differences for the LASER key symptoms were observed. The observed differences in long-term HRQL are in favor of patients treated with neoadjuvant chemoradiotherapy compared with patients treated with perioperative chemotherapy; however, the differences were small. Patients need to be informed about long-term HRQL when considering allocation of (neo)adjuvant treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: Analysis from the population-based POCOP study

Author

Dutch Upper GI Canc Grp DUCG, van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G-J, Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., van Laarhoven, H. W. M., Dutch Upper GI Canc Grp DUCG, van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G-J, Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., and van Laarhoven, H. W. M.

Abstract

Background Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer. Methods Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS. Results In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82-0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59-0.94), followed by fatigue, pain, insomnia and role functioning. Conclusion In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models.

Published
2021

19. Re-evaluating randomized clinical trials of psychological interventions: Impact of response shift on the interpretation of trial results

Author

Verdam, M. G. E., primary, van Ballegooijen, W., additional, Holtmaat, C. J. M., additional, Knoop, H., additional, Lancee, J., additional, Oort, F. J., additional, Riper, H., additional, van Straten, A., additional, Verdonck-de Leeuw, I. M., additional, de Wit, M., additional, van der Zweerde, T., additional, and Sprangers, M. A. G., additional

Published
2021
Full Text
View/download PDF

32. Postoperative Complications and Long-Term Quality of Life After Multimodality Treatment for Esophageal Cancer: An Analysis of the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP).

Author

Jezerskyte, E., van Berge Henegouwen, M. I., van Laarhoven, H. W. M., van Kleef, J. J., Eshuis, W. J., Heisterkamp, J., Hartgrink, H. H., Rosman, C., van Hillegersberg, R., Hulshof, M. C. C. M., Sprangers, M. A. G., and Gisbertz, S. S.

Abstract

Background: Esophagectomy has major effects on health-related quality of life (HR-QoL). Postoperative complications might contribute to a decreased HR-QOL. This population-based study aimed to investigate the difference in HR-QoL between patients with and without complications after esophagectomy for cancer. Methods: A prospective comparative cohort study was performed with data from the Netherlands Cancer Registry (NCR) and Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP). All patients with esophageal and gastroesophageal junction (GEJ) cancer after esophagectomy in the period 2015–2018 were enrolled. The study investigated HR-QoL at baseline, then 3, 6, 9, 12, 18, and 24 months postoperatively, comparing patients with and without complications as well as with and without anastomotic leakage. Results: The 486 enrolled patients comprised 270 patients with complications and 216 patients without complications. Significantly more patients with complications had comorbidities (69.6% vs 57.3%; p = 0.001). No significant difference in HR-QoL was found over time between the patients with and without complications. In both groups, a significant decline in short-term HR-QoL was found in various HR-QoL domains, which were restored to the baseline level during the 12-month follow-up period. No significant difference was found in HR-QoL between the patients with and without anastomotic leakage. The patients with grades 2 and 3 anastomotic leakage reported significantly more "choking when swallowing" at 6 months (ß = 14.5; 95% confidence interval [CI], − 24.833 to − 4.202; p = 0.049), 9 months (ß = 22.4, 95% CI, − 34.259 to − 10.591; p = 0.007), and 24 months (ß = 24.6; 95% CI, − 39.494 to − 9.727; p = 0.007) than the patients with grade 1 or no anastomotic leakage. Conclusion: In general, postoperative complications were not associated with decreased short- or long-term HR-QoL for patients after esophagectomy for esophageal or GEJ cancer. The temporary decrease in HR-QoL likely is related to the nature of esophagectomy and reconstruction itself. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study.

Author

van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G.-J., Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., and van Laarhoven, H. W. M.

Subjects
QUALITY of life, PROGNOSIS, OVERALL survival, PROPORTIONAL hazards models, PROGNOSTIC models
Abstract

Background: Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer. Methods: Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS. Results: In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82–0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59–0.94), followed by fatigue, pain, insomnia and role functioning. Conclusion: In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Nationwide comprehensive gastro-intestinal cancer cohorts : The 3P initiative

Author

van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

43. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

44. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., Van Laarhoven, H. W. M., Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and Van Laarhoven, H. W. M.

Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged 18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses

Published
2018

45. Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy.

Author

Musoro, J. Z., Sodergren, S. C., Coens, C., Pochesci, A., Terada, M., King, M. T., Sprangers, M. A. G., Groenvold, M., Cocks, K., Velikova, G., Flechtner, H.‐H., and Bottomley, A.

Subjects
CANCER chemotherapy, COLORECTAL cancer, QUALITY of life, ABSOLUTE value, EXPERIMENTAL design
Abstract

Aim: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) assesses the health‐related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ‐C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ‐C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials. Method: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ‐C30 scales. Anchor‐based MIDs for within‐group change and between‐group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution‐based MIDs were also examined. Results: Anchor‐based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ‐C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (−11 to −5) points for within‐group change and 5 to 15 (−10 to −4) for between‐group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points. Conclusions: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients

Author

De Boer, A. G., Bockting, C. L. H., Bennebroek Evertsz', F., Stokkers, P. C., Sandeman, R., Hommes, D. W., Sprangers, M. A. G., Frings-Dresen, M. H. W., Leerstoel Bockting, Trauma and Grief, Clinical Psychology and Experimental Psychopathology, Health Psychology Research (HPR), Coronel Institute of Occupational Health, Medical Psychology, and Other departments

Subjects
Male, Social Sciences, Efficiency, Disease, Hospital Anxiety and Depression Scale, Inflammatory bowel disease, FATIGUE, 0302 clinical medicine, Cost of Illness, Crohn Disease, Quality of life, Risk Factors, Absenteeism, Medicine, 030212 general & internal medicine, PREDICTORS, Depression (differential diagnoses), disability pension, Netherlands, Gastroenterology, Middle Aged, anxiety, DEPRESSION, Sick leave, employment, Health Resources, Anxiety, Female, 030211 gastroenterology & hepatology, TRIAL, medicine.symptom, Adult, medicine.medical_specialty, concentration, Adolescent, QUESTIONNAIRE, sick leave, VALIDATION, Pensions, Young Adult, 03 medical and health sciences, work, inflammatory bowel disease, Humans, Psychiatry, Hepatology, business.industry, DISABILITY, Disability pension, medicine.disease, digestive system diseases, Cross-Sectional Studies, quality of life, RISK-FACTORS, Colitis, Ulcerative, Self Report, business
Abstract

ObjectivesTo assess employment status, difficulties at work and sick leave in inflammatory bowel disease (IBD) patients and their relation with sociodemographic and clinical factors, quality of life (QoL), and anxiety and depression.Materials and methodsIBD patients attending an IBD outpatients' clinic received self-report questionnaires on employment status, IBD-related difficulties at work and sick leave (Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness), sociodemographic factors, QoL (Inflammatory Bowel Disease Questionnaire and 12-item Short-form Health Survey) and anxiety and depression (Hospital Anxiety and Depression Scale). Disease activity was assessed by their gastroenterologist. Associations between paid employment and sick leave with sociodemographic and clinical factors, QoL and anxiety and depression were assessed by regression analyses.ResultsIn total, 202 IBD patients of working age, with a mean age of 41 years, participated; 63% had Crohn's disease and 37% had ulcerative colitis, and 57% were women and 19% had active disease. In all, 123 (61%) patients were in paid employment, of whom 31 (25%) were on sick leave, whereas 46 (23%) received a disability pension. Concentration problems (72%), low working pace (78%) and delayed work production (50%) were the most prevalent IBD-related work difficulties. IBD patients without paid employment were older and more often women, with active disease, lower QoL and higher anxiety and depression rates. Sick leave was associated with lower QoL and higher anxiety and depression rates.ConclusionMore than half of IBD patients were in paid employment, whereas almost a quarter was receiving a disability pension. A large majority experienced work difficulties. Having no paid employment was associated with poorer QoL and more anxiety and depression symptomatology.

Published
2016

49. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients

Author

Leerstoel Bockting, Trauma and Grief, De Boer, A. G., Bockting, C. L. H., Bennebroek Evertsz', F., Stokkers, P. C., Sandeman, R., Hommes, D. W., Sprangers, M. A. G., Frings-Dresen, M. H. W., Leerstoel Bockting, Trauma and Grief, De Boer, A. G., Bockting, C. L. H., Bennebroek Evertsz', F., Stokkers, P. C., Sandeman, R., Hommes, D. W., Sprangers, M. A. G., and Frings-Dresen, M. H. W.

Published
2016

50. A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial

Author

Langebeek, N., Sprenger, H. G., Gisolf, E. H., Reiss, P., Sprangers, M. A. G., Legrand, Jc, Richter, C., Nieuwkerk, P. T., Graduate School, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, Cancer Center Amsterdam, and Medical Psychology

Subjects
ABACAVIR/LAMIVUDINE/ZIDOVUDINE, HAART, INDUCTION, simplified regimen, antiretroviral therapy, IMPROVES ADHERENCE, QUESTIONNAIRE, HIV-INFECTED PATIENTS, treatment satisfaction, LAMIVUDINE, compliance, VALIDATION, MAINTENANCE, quality of life, randomized controlled trial, ABACAVIR, adherence
Abstract

Objectives The aim of the study was to investigate the effect of a simplified regimen, in terms of reducing pill burden, dietary requirements and possible adverse effects, on patients' adherence, treatment satisfaction and quality of life (QoL). Methods Antiretroviral-naive patients who achieved a viral load

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results